Hepatitis B virus genotype: What should the clinician know?

Liu, Chun‐Jen; Kao, Jia‐Horng

doi:10.1007/bf02942174

Cited by 7 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HBV genotypes were previously shown to have distinct geographic and ethnic distribution, with genotypes B and C prevailing in Southeast Asia [8] , and our present study further confirmed this finding. Moreover, HBV genotypes were previously demonstrated to influence the natural course of liver disease progression in HBV carriers in Asian countries [9] .…”

supporting

confidence: 81%

Characterization of Hepatitis B Virus Molecular Genotypes in Chongqing and Quantitative Serological Markers in Patients during Natural Phases of Chronic Hepatitis B Infection

Yu¹,

Huang²,

Xia³

et al. 2011

Intervirology

View full text Add to dashboard Cite

Background/Aims: The present study was launched to systematically characterize the molecular genotypes and quantitative serological biomarkers during the natural course of chronic hepatitis B (CHB) infection in a patient population from Chongqing, China. Methods: A total of 140 patients were enrolled and grouped according to the natural phases of HBV infection: HBeAg (+) immune tolerance, immune clearance, HBeAg (–) low replicative and reactivation phase. Nested PCR was used for HBV molecular genotyping and chemiluminescent microparticle immunoassay for quantitative serological detection. Results: Subgenotypes B2 and C2 were found to be most prevalent with genotype B patients showing more potent viral activity. HBsAg level was found to be significantly correlated with HBV DNA, HBeAg, age, ALT and AST levels during some phases of CHB. Conclusion: These results indicated that molecular genotyping and quantitative serological detection might be helpful for earlier prediction of the long-term disease outcomes.

show abstract

supporting

confidence: 81%

Characterization of Hepatitis B Virus Molecular Genotypes in Chongqing and Quantitative Serological Markers in Patients during Natural Phases of Chronic Hepatitis B Infection

Yu¹,

Huang²,

Xia³

et al. 2011

Intervirology

View full text Add to dashboard Cite

show abstract

“…Owing to the unique distribution of HBV genotypes in Eastern and Western countries, the therapeutic implications of HBV genotype could only be compared between genotypes B and C or genotypes A and D. For further details, please see reviews [43,104].…”

Section: Genotypesmentioning

confidence: 99%

Role of viral factors in the natural course and therapy of chronic hepatitis B

Kao

2007

Hepatol Int

Self Cite

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a global health problem that causes a wide spectrum of liver disease, including acute or fulminant hepatitis, inactive carrier state, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The pathogenesis of hepatocyte damage associated with HBV is mainly through immune-mediated mechanisms. On the basis of the virus and host interactions, the natural history of HBV carriers who are infected in early life can be divided into four dynamic phases. The frequency, extent, and severity of hepatitis flares or acute exacerbation in the second immune clearance and/or fourth reactivation phase predict liver disease progression in HBV carriers. In the past decade, hepatitis B viral factors including serum HBV DNA level, genotype, and naturally occurring mutants predictive of clinical outcomes have been identified. The higher the serum HBV DNA level after the immune clearance phase, the higher the incidence of adverse outcomes over time. In addition, high viral load, genotype C, basal core promoter mutation, and pre-S deletion correlate with increased risk of cirrhosis and HCC development. As to the treatment of chronic hepatitis B, patients with high HBV DNA level and genotype C or D infection are shown to have a worse response to interferon therapy. In conclusion, serum HBV DNA level, genotype, and naturally occurring mutants are identified to influence liver disease progression and therapy of chronic hepatitis B. More investigations are needed to clarify the molecular mechanisms of the viral factors involved in the pathogenesis of each stage of liver disease and the response to antiviral treatments.

show abstract

“…O genótipo B é associado a altas taxas de soroconversão do HBeAg para anti-HBe quando comparadas com o genótipo C 21 27 . A seleção da mutação pré-core (anti-HBe reativo) é relatada entre portadores do genótipo B, a variante pré-core é mais comum em pacientes com genótipo D e raramente entre os com genótipo A. Portadores do VHB mutante pré-core ou promoter core basal (hepatite crônica B HBeAg negativo) com genótipo D apresentam resistência significativa à lamivudina (rtM2041) 27 . Em Taiwan, o genótipo B do VHB predomina entre crianças portadoras crônicas do VHB e com quadro de câncer de fígado 27 .…”

Section: Características Biológicas Do Vírus Da Hepatite Bunclassified

“…A seleção da mutação pré-core (anti-HBe reativo) é relatada entre portadores do genótipo B, a variante pré-core é mais comum em pacientes com genótipo D e raramente entre os com genótipo A. Portadores do VHB mutante pré-core ou promoter core basal (hepatite crônica B HBeAg negativo) com genótipo D apresentam resistência significativa à lamivudina (rtM2041) 27 . Em Taiwan, o genótipo B do VHB predomina entre crianças portadoras crônicas do VHB e com quadro de câncer de fígado 27 . Por outro lado, crianças portadoras do genótipo C do VHB apresentam: maior freqüência de soroconversão para o HBeAg, alta freqüência de mutação core promoter, alta atividade das aminotransferases e, finalmente, baixa resposta à terapia com Interferon alfa 21 27 32 .…”

Section: Características Biológicas Do Vírus Da Hepatite Bunclassified

História natural da hepatite crônica B

Fonseca

2007

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

RESUMO Estima ABSTRACT An estimated 350 million people worldwide are chronically infected with hepatitis B virus (HBV). Three phases of chronic hepatitis B virus infection is are recognized: the immune tolerant phase (HBeAg-positive, high levels of serum HBV-DNA, normal ALT, and no evidence of active liver diseases), the immune clearance phase or chronic hepatitis phase (HBeAg-positive, high levels of serum HBV-DNA, elevated ALT, and active liver disease ), and the inactive carrier state or asymptomatic phase (HBsAg-positive in serum without HBeAg, HBV-DNA levels than < 10 5 copies/mL, and normal ALT levels). �hronic hepatitis B is classified into 2 major forms: HBeAg-positive disease (wild-type HBV) and HBeAg negative disease (pre-core/core promoter HBV variant). Both forms can lead to liver cirrhosis, hepatic decompensation and liver cancer. The purpose of this article is to review the principal aspects of natural history of chronic hepatitis B. Key.

show abstract

Hepatitis B virus genotype: What should the clinician know?

Cited by 7 publications

References 56 publications

Characterization of Hepatitis B Virus Molecular Genotypes in Chongqing and Quantitative Serological Markers in Patients during Natural Phases of Chronic Hepatitis B Infection

Characterization of Hepatitis B Virus Molecular Genotypes in Chongqing and Quantitative Serological Markers in Patients during Natural Phases of Chronic Hepatitis B Infection

Role of viral factors in the natural course and therapy of chronic hepatitis B

História natural da hepatite crônica B

Contact Info

Product

Resources

About